Silengenics is developing SIG-001, a GalNAc‑conjugated siRNA that selectively silences a liver gene to reduce hepatic lipid accumulation and boost triglyceride clearance. Administered as a single subcutaneous injection, the therapy aims to treat both MASLD/MASH and atherogenic dyslipidemia, lowering fibrosis progression and cardiovascular risk. The platform leverages proven GalNAc‑siRNA delivery for a long‑acting, infrequent dosing regimen.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD/MASH) often have concurrent atherogenic dyslipidemia, type‑2 diabetes, and obesity, creating a combined cardiometabolic risk that drives both liver fibrosis and cardiovascular events. Current therapies address either liver disease or lipid risk, leaving a large patient population without a treatment that tackles both pathways simultaneously.
Solution
Silengenics is developing SIG‑001, a GalNAc‑conjugated siRNA that silences a liver‑expressed gene central to lipid metabolism. A single subcutaneous injection delivers the drug selectively to hepatocytes via the ASGPR receptor, providing long‑acting suppression of hepatic lipid accumulation and activation of the lipoprotein lipase pathway to enhance triglyceride clearance. Human genetic data support the target’s causal role in lowering triglycerides, apoB, and liver disease, de‑risking the therapeutic hypothesis. The platform leverages the same validated GalNAc‑siRNA delivery used in approved medicines, enabling a streamlined regulatory path. By addressing both hepatic steatosis and atherogenic dyslipidemia with one dose, SIG‑001 aims to reduce progression to fibrosis and lower cardiovascular risk in the billions of adults affected by overlapping cardiometabolic disease.
Target Audience
Primary customers are pharmaceutical partners and clinical research organizations developing therapies for MASLD/MASH, atherogenic dyslipidemia, and broader cardiometabolic indications.
Features
- GalNAc‑siRNA chemistry that targets the asialoglycoprotein receptor for selective liver delivery and proven safety in approved drugs
- Single‑dose, long‑acting regimen designed for infrequent administration (e.g., quarterly or semi‑annual)
- Dual mechanism: reduces hepatic lipid storage and activates lipoprotein lipase to accelerate triglyceride‑rich lipoprotein clearance
- Human genetic validation of the target, linking loss‑of‑function variants to lower triglycerides, apoB, and reduced liver disease
- Pre‑clinical program with IND‑enabling studies planned for 2026–2027 and Phase 1/2a clinical timelines through 2030–2031